Secondary structure and toxicity of lysozyme fibrils are determined by the length and unsaturation of phosphatidic acid.
LDH
amyloid fibrils
lysozyme
phosphatidic acid
Journal
Proteins
ISSN: 1097-0134
Titre abrégé: Proteins
Pays: United States
ID NLM: 8700181
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
revised:
11
09
2023
received:
12
06
2023
accepted:
12
10
2023
medline:
1
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
aheadofprint
Résumé
A progressive aggregation of misfolded proteins is a hallmark of numerous pathologies including diabetes Type 2, Alzheimer's disease, and Parkinson's disease. As a result, highly toxic protein aggregates, which are known as amyloid fibrils, are formed. A growing body of evidence suggests that phospholipids can uniquely alter the secondary structure and toxicity of amyloid aggregates. However, the role of phosphatidic acid (PA), a unique lipid that is responsible for cell signaling and activation of lipid-gated ion channels, in the aggregation of amyloidogenic proteins remains unclear. In this study, we investigate the role of the length and degree of unsaturation of fatty acids (FAs) in PA in the structure and toxicity of lysozyme fibrils formed in the presence of this lipid. We found that both the length and saturation of FAs in PA uniquely altered the secondary structure of lysozyme fibrils. However, these structural differences in PA caused very little if any changes in the morphology of lysozyme fibrils. We also utilized cell toxicity assays to determine the extent to which the length and degree of unsaturation of FAs in PA altered the toxicity of lysozyme fibrils. We found that amyloid fibrils formed in the presence of PA with C18:0 FAs exerted significantly higher cell toxicity compared to the aggregates formed in the presence of PA with C16:0 and C18:1 FAs. These results demonstrated that PA can be an important player in the onset and spread of amyloidogenic diseases.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIGMS NIH HHS
Pays : United States
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Knowles TP, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat Rev. 2014;15(6):384-396.
Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991;1(3):213-216.
Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem. 1999;274(33):23223-23228.
Chiti F, Dobson CM. Protein Misfolding, amyloid formation, and human disease: a summary of Progress over the last decade. Annu Rev Biochem. 2017;86(1):27-68.
Nelson R, Eisenberg D. Structural models of amyloid-like fibrils. Adv Protein Chem. 2006;73:235-282.
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356.
Ghosh U, Thurber KR, Yau WM, Tycko R. Molecular structure of a prevalent amyloid-beta fibril polymorph from Alzheimer's disease brain tissue. Proc Natl Acad Sci U S A. 2021;118(4):e2023089118.
Almeida CG, Takahashi RH, Gouras GK. Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci. 2006;26(16):4277-4288.
Eisenberg DS, Sawaya MR. Structural studies of amyloid proteins at the molecular level. Annu Rev Biochem. 2017;86:69-95.
Gallardo R, Ranson NA, Radford SE. Amyloid structures: much more than just a cross-beta fold. Curr Opin Struct Biol. 2020;60:7-16.
Ghosh U, Yau WM, Collinge J, Tycko R. Structural differences in amyloid-beta fibrils from brains of nondemented elderly individuals and Alzheimer's disease patients. Proc Natl Acad Sci U S A. 2021;118(45):e2111863118.
Nelson R, Eisenberg D. Recent atomic models of amyloid fibril structure. Curr Opin Struct Biol. 2006;16(2):260-265.
Iadanza MG, Jackson MP, Hewitt EW, Ranson NA, Radford SE. A new era for understanding amyloid structures and disease. Nat Rev Mol Cell Biol. 2018;19(12):755-773.
Kurouski D, Lu X, Popova L, et al. Is supramolecular filament chirality the underlying cause of major morphology differences in amyloid fibrils? J Am Chem Soc. 2014;136(6):2302-2312.
Han S, Kollmer M, Markx D, Claus S, Walther P, Fandrich M. Amyloid plaque structure and cell surface interactions of beta-amyloid fibrils revealed by electron tomography. Sci Rep. 2017;7:43577.
Chauhan A, Ray I, Chauhan VP. Interaction of amyloid beta-protein with anionic phospholipids: possible involvement of Lys28 and C-terminus aliphatic amino acids. Neurochem Res. 2000;25(3):423-429.
Chi EY, Ege C, Winans A, et al. Lipid membrane templates the ordering and induces the fibrillogenesis of Alzheimer's disease amyloid-beta peptide. Proteins. 2008;72(1):1-24.
Galvagnion C, Brown JW, Ouberai MM, et al. Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of alpha-synuclein. Proc Natl Acad Sci USA. 2016;113(26):7065-7070.
Galvagnion C, Buell AK, Meisl G, et al. Lipid vesicles trigger alpha-synuclein aggregation by stimulating primary nucleation. Nat Chem Biol. 2015;11(3):229-234.
Zhaliazka K, Kurouski D. Nanoscale characterization of parallel and antiparallel beta-sheet amyloid beta 1-42 aggregates. ACS Chem Nerosci. 2022;13(19):2813-2820.
Matveyenka M, Rizevsky S, Kurouski D. Unsaturation in the fatty acids of phospholipids drastically alters the structure and toxicity of insulin aggregates grown in their presence. J Phys Chem Lett. 2022;13:4563-4569.
Matveyenka M, Rizevsky S, Pellois JP, Kurouski D. Lipids uniquely alter rates of insulin aggregation and lower toxicity of amyloid aggregates. Biochim Biophys Acta Mol Cell Biol Lipids. 2023;1868(1):159247.
Matveyenka M, Rizevsky S, Kurouski D. The degree of unsaturation of fatty acids in phosphatidylserine alters the rate of insulin aggregation and the structure and toxicity of amyloid aggregates. FEBS Lett. 2022;596(11):1424-1433.
Matveyenka M, Rizevsky S, Kurouski D. Length and unsaturation of fatty acids of phosphatidic acid determines the aggregation rate of insulin and modifies the structure and toxicity of insulin aggregates. ACS Chem Nerosci. 2022;13(16):2483-2489.
Matveyenka M, Rizevsky S, Kurouski D. Amyloid aggregates exert cell toxicity causing irreversible damages in the endoplasmic reticulum. Biochim Biophys Acta Mol Basis Dis. 2022;1868(11):166485.
Matveyenka M, Zhaliazka K, Rizevsky S, Kurouski D. Lipids uniquely alter secondary structure and toxicity of lysozyme aggregates. FASEB J. 2022;36(10):e22543.
Tanguy E, Wang QL, Moine H, Vitale N. Phosphatidic acid: from pleiotropic functions to neuronal pathology. Front Cell Neurosci. 2019;13:2.
Bader MF, Vitale N. Phospholipase D in calcium-regulated exocytosis: lessons from chromaffin cells. Biochim Biophys Acta. 2009;1791:936-941.
Stace CL, Ktistakis NT. Phosphatidic acid- and phosphatidylserine-binding proteins. Biochim Biophys Acta. 2006;1761:913-926.
Mizuno S, Sasai H, Kume A, et al. Dioleoyl-phosphatidic acid selectively binds to alpha-synuclein and strongly induces its aggregation. FEBS Lett. 2017;591(5):784-791.
Fitzner D, Bader JM, Penkert H, et al. Cell-type- and brain-region-resolved mouse brain Lipidome. Cell Rep. 2020;32(11):108132.
McMahon HT, Gallop JL. Membrane curvature and mechanisms of dynamic cell membrane remodelling. Nature. 2005;438(7068):590-596.
Pleyer C, Flesche J, Saeed F. Lysozyme amyloidosis-a case report and review of the literature. Clin Nephrol Case Stud. 2015;3:42-45.
Kayed R, Lasagna-Reeves CA. Molecular mechanisms of amyloid oligomers toxicity. J Alzheimers Dis. 2013;33(suppl 1):S67-S78.
Cerf E, Sarroukh R, Tamamizu-Kato S, et al. Antiparallel beta-sheet: a signature structure of the oligomeric amyloid beta-peptide. Biochem J. 2009;421(3):415-423.
O'Leary EI, Lee JC. Interplay between alpha-synuclein amyloid formation and membrane structure. Biochim Biophys Acta Proteins Proteom. 2019;1867(5):483-491.
Ysselstein D, Joshi M, Mishra V, et al. Effects of impaired membrane interactions on α-synuclein aggregation and neurotoxicity. Neurobiol Dis. 2015;79:150-163.
Bodner CR, Dobson CM, Bax A. Multiple tight phospholipid-binding modes of α-synuclein revealed by solution NMR spectroscopy. J Mol Biol. 2009;390(4):775-790.
Maltsev AS, Chen J, Levine RL, Bax A. Site-specific interaction between α-synuclein and membranes probed by NMR-observed methionine oxidation rates. J Am Chem Soc. 2013;135(8):2943-2946.
Bodner CR, Maltsev AS, Dobson CM, Bax A. Differential phospholipid binding of α-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy. Biochemistry. 2010;49(5):862-871.
Rizevsky S, Matveyenka M, Kurouski D. Nanoscale structural analysis of a lipid-driven aggregation of insulin. J Phys Chem Lett. 2022;13(10):2467-2473.
Dou T, Kurouski D. Phosphatidylcholine and phosphatidylserine uniquely modify the secondary structure of alpha-synuclein oligomers formed in their presence at the early stages of protein aggregation. ACS Chem Nerosci. 2022;13(16):2380-2385.
Dou T, Zhou L, Kurouski D. Unravelling the structural Organization of Individual alpha-synuclein oligomers grown in the presence of phospholipids. J Phys Chem Lett. 2021;12(18):4407-4414.
Zhaliazka K, Kurouski D. Lipids uniquely Alter the secondary structure and toxicity of amyloid beta 1-42 aggregates. FEBS J. 2023;290:3203-3220. doi:10.1111/febs.16738
Zhang X, St Clair JR, London E, Raleigh DP. Islet amyloid polypeptide membrane interactions: effects of membrane composition. Biochemistry. 2017;56(2):376-390.
Kurouski D, Deckert-Gaudig T, Deckert V, Lednev IK. Structure and composition of insulin fibril surfaces probed by TERS. J Am Chem Soc. 2012;134(32):13323-13329.
Kurouski D, Postiglione T, Deckert-Gaudig T, Deckert V, Lednev IK. Amide I vibrational mode suppression in surface (SERS) and tip (TERS) enhanced Raman spectra of protein specimens. Analyst. 2013;138(6):1665-1673.
D'Souza A, Theis JD, Vrana JA, Buadi F, Dispenzieri A, Dogan A. Localized insulin-derived amyloidosis: a potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. Am J Hematol. 2012;87(11):E131-E132.
Gupta Y, Singla G, Singla R. Insulin-derived amyloidosis. Indian J Endocrinol Metab. 2015;19(1):174-177.
Shikama Y, Kitazawa J, Yagihashi N, et al. Localized amyloidosis at the site of repeated insulin injection in a diabetic patient. Intern Med. 2010;49(5):397-401.
Holman AP, Quinn K, Kumar R, Kmiecik S, Ali A, Kurouski D. Fatty acids reverse supramolecular chirality of insulin fibrils. J Phys Chem Lett. 2023;14:6935-6939.